<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2803245125
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VIAGRA 50 mg Orodispersible Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SILDENAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        132.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Fareva Amboise" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Fareva Amboise
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            UPJOHN EESV
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VIAGRA contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. It works by helping to relax the blood vessels in your penis, allowing blood to flow into your penis when you get sexually excited. VIAGRA will only help you to get an erection if you are sexually stimulated.</p><p>VIAGRA is a treatment for adult men with erectile dysfunction, sometimes known as impotence. This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take VIAGRA</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to sildenafil or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking medicines called nitrates, as the combination may lead to a dangerous fall in your blood pressure. Tell your doctor if you are taking any of these medicines which are often given for relief of angina pectoris (or &ldquo;chest pain&rdquo;). If you are not certain, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are using any of the medicines known as nitric oxide donors such as amyl nitrite (&ldquo;poppers&rdquo;), as the combination may also lead to a dangerous fall in your blood pressure.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking riociguat. This drug is used to treat pulmonary arterial hypertension (i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as Viagra have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a severe heart or liver problem.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have recently had a stroke or a heart attack, or if you have low blood pressure.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have certain rare inherited eye diseases (such as <em>retinitis pigmentosa</em>).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had loss of vision due to non‑arteritic anterior ischaemic optic neuropathy (NAION).</p><p><em>&nbsp;</em></p><p>Warnings and precautions</p><p>Talk to your doctor, pharmacist or nurse before taking VIAGRA</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have sickle cell anaemia (an abnormality of red blood cells), leukaemia (cancer of blood cells), multiple myeloma (cancer of bone marrow).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a deformity of your penis or Peyronie&rsquo;s Disease.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have problems with your heart. Your doctor should carefully check whether your heart can take the additional strain of having sex.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you currently have a stomach ulcer, or a bleeding problems (such as haemophilia).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience sudden decrease or loss of vision, stop taking&nbsp;VIAGRA and contact your doctor immediately.</p><p><em>&nbsp;</em></p><p>You should not use VIAGRA with any other oral or local treatments for erectile dysfunction.</p><p>You should not use VIAGRA with treatments for pulmonary arterial hypertension (PAH) containing sildenafil or any other PDE5 inhibitors.</p><p>&nbsp;</p><p>You should not take VIAGRA if you do not have erectile dysfunction.</p><p>&nbsp;</p><p>You should not take VIAGRA if you are a woman.</p><p><strong>&nbsp;</strong></p><p><em>Special considerations for patients with kidney or liver problems</em></p><p>You should tell your doctor if you have kidney or liver problems. Your doctor may decide on a lower dose for you.</p><p>&nbsp;</p><p>Children and adolescents</p><p>VIAGRA should not be given to individuals under the age of 18.</p><p>&nbsp;</p><p><strong>Other medicines and VIAGRA</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>VIAGRA tablets may interfere with some medicines, especially those used to treat chest pain. In the event of a medical emergency, you should tell your doctor, pharmacist or nurse that you have taken VIAGRA and when you did. Do not take VIAGRA with other medicines unless your doctor tells you that you can.</p><p>&nbsp;</p><p>You should not take VIAGRA if you are taking medicines called nitrates, as the combination of these medicines may lead to a dangerous fall in your blood pressure. Always tell your doctor, pharmacist or nurse if you are taking any of these medicines that are often used for the relief of angina pectoris (or &ldquo;chest pain&rdquo;).</p><p><strong>&nbsp;</strong></p><p>You should not take VIAGRA if you are using any of the medicines known as nitric oxide donors such as amyl nitrite (&ldquo;poppers&rdquo;) as the combination may also lead to a dangerous fall in your blood pressure.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are already taking riociguat.</p><p><strong>&nbsp;</strong></p><p>If you are taking medicines known as protease inhibitors, such as for the treatment of HIV, your doctor may start you on the lowest dose (25&nbsp;mg film‑coated tablets) of VIAGRA.</p><p>&nbsp;</p><p>Some patients who take alpha‑blocker therapy for the treatment of high blood pressure or prostate enlargement may experience dizziness or light‑headedness, which may be caused by low blood pressure upon sitting or standing up quickly. Certain patients have experienced these symptoms when taking VIAGRA with alpha‑blockers. This is most likely to happen within 4 hours after taking VIAGRA. To reduce the chance that these symptoms might happen, you should be on a regular daily dose of your alpha‑blocker before you start VIAGRA. Your doctor may start you on a lower dose (25&nbsp;mg film-coated tablets) of VIAGRA.</p><p>&nbsp;</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking medicines containing sacubitril/valsartan, used to treat heart failure.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>VIAGRA with alcohol</strong></p><p>Drinking alcohol can temporarily impair your ability to get an erection. To get the maximum benefit from your medicine, you are advised not to drink excessive amounts of alcohol before taking VIAGRA.</p><p>&nbsp;</p><p><strong>Pregnancy, breast‑feeding and fertility</strong></p><p>VIAGRA is not indicated for use by women.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>VIAGRA can cause dizziness and can affect vision. You should be aware of how you react to VIAGRA before you drive or use machinery.</p><p>&nbsp;</p><p><strong>VIAGRA contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended starting dose is 50&nbsp;mg.</p><p>&nbsp;</p><p><strong><em>You should not take VIAGRA more than once a day.</em></strong></p><p>&nbsp;</p><p>Do not take VIAGRA orodispersible tablets in combination with film‑coated tablets containing sildenafil including VIAGRA film‑coated tablets.</p><p>&nbsp;</p><p>You should take VIAGRA about one hour before you plan to have sex. The amount of time VIAGRA takes to work varies from person to person, but it normally takes between half an hour and one hour.</p><p>&nbsp;</p><p>Place the orodispersible tablet in the mouth, on the tongue, where it will dissolve in seconds, then swallow with saliva or water.</p><p>&nbsp;</p><p>The orodispersible tablets should be taken on an empty stomach as you may find that it takes longer to start working if you take it with a heavy meal.</p><p>&nbsp;</p><p>If you require a second 50&nbsp;mg orodispersible tablet to make a 100&nbsp;mg dose, you should wait until the first one has completely disintegrated and you have swallowed it before taking the second orodispersible tablet.</p><p>&nbsp;</p><p>If you feel that the effect of VIAGRA is too strong or too weak, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>VIAGRA will only help you to get an erection if you are sexually stimulated.</p><p>&nbsp;</p><p>If VIAGRA does not help you to get an erection, or if your erection does not last long enough for you to complete sexual intercourse you should tell your doctor.</p><p>&nbsp;</p><p>If you take more VIAGRA than you should:</p><p>You may experience an increase in side effects and their severity. Doses above 100&nbsp;mg do not increase the efficacy.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>You should not take more tablets than your doctor tells you to. </em></strong></p><p>&nbsp;</p><p>Contact your doctor if you take more tablets than you should.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects although not everybody gets them. The side effects reported in association with the use of VIAGRA are usually mild to moderate and of a short duration.</p><p>&nbsp;</p><p><strong>If you experience any of the following serious side effects stop taking VIAGRA and seek medical help immediately:</strong></p><p>&nbsp;</p><ul><li>An allergic reaction &ndash; (this occurs <strong>uncommonly</strong> may affect up to 1 in 100 people)</li></ul><p>Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.</p><p>&nbsp;</p><ul><li>Chest pains - this occurs <strong>uncommonly </strong></li></ul><p>If this occurs during or after intercourse:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Get in a semi‑sitting position and try to relax.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - <strong>Do not use nitrates </strong>to treat your chest pain.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; &nbsp;&nbsp; Prolonged and sometimes painful erections &ndash; this occurs <strong>rarely </strong>(may affect up to 1 in 1,000 people)</p><p>If you have an erection which lasts for more than 4 hours, you should contact a doctor immediately.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; &nbsp;&nbsp; A sudden decrease or loss of vision - this occurs <strong>rarely</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; &nbsp;&nbsp; Serious skin reactions - this occurs <strong>rarely</strong></p><p>Symptoms may include severe peeling and swelling of the skin, blistering of the mouth, genitals and around the eyes, fever.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; &nbsp;&nbsp; Seizures or fits - this occurs <strong>rarely</strong></p><p>&nbsp;</p><p><strong>Other side effects:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10 people): headache.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people): nausea, facial flushing, hot flush (symptoms include a sudden feeling of heat in your upper body), indigestion, colour tinge to vision, blurred vision, visual disturbance, stuffy nose and dizziness.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people): vomiting, skin rash, eye irritation, bloodshot eyes /red eyes, eye pain, seeing flashes of light, visual brightness, light sensitivity, watery eyes, pounding heartbeat, rapid heartbeat, high blood pressure, low blood pressure, muscle pain, feeling sleepy, reduced sense of touch, vertigo, ringing in the ears, dry mouth, blocked or stuffy sinuses,<em> </em>inflammation of the lining of the nose (symptoms include runny nose, sneezing and stuffy nose), upper abdominal pain, gastro-oesophageal reflux disease (symptoms include heartburn), presence of blood in urine, pain in the arms or legs, nosebleed, feeling hot and feeling tired.</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people): fainting, stroke, heart attack, irregular heartbeat, temporary decreased blood flow to parts of the brain, feeling of tightening of the throat, numb mouth, bleeding at the back of the eye, double vision, reduced sharpness of vision, abnormal sensation in the eye, swelling of the eye or eyelid, small particles or spots in your vision, seeing halos around lights, dilation of the pupil of the eye, discolouration of the white of the eye, penile bleeding, presence of blood in semen, dry nose, swelling of the inside of the nose, feeling irritable and sudden decrease or loss of hearing.<strong> </strong></p><p>&nbsp;</p><p>From post-marketing experience cases of unstable angina (a heart condition) and sudden death have been reported rarely. Of note, most, but not all, of the men who experienced these side effects had heart problems before taking this medicine. It is not possible to determine whether these events were directly related to VIAGRA.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>To report side effects</strong></p><p>&nbsp;</p><ul><li><!--[if gte vml 1]><v:shapetype
      id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
      <v:stroke joinstyle="miter"/>
      <v:path gradientshapeok="t" o:connecttype="rect"/>
     </v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
      type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
      margin-left:0;margin-top:27.1pt;width:481.5pt;height:70pt;text-indent:0;
      z-index:251661312;visibility:visible;mso-wrap-style:square;
      mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
      mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
      mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:left;
      mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
      mso-position-vertical-relative:text;mso-width-percent:0;
      mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
      v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokeweight=".5pt">
      <v:textbox>
       <![if !mso]>
       <table cellpadding=0 cellspacing=0 width="100%">
        <tr>
         <td><![endif]>
         <div>
         <p class=MsoNormal><b><span lang=EN-GB style='mso-bidi-font-size:11.0pt'>National
         Pharmacovigilance Centre ( NPC )</span></b><b><span lang=EN-GB
         style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:Calibri'><o:p></o:p></span></b></p>
         <ul style='margin-top:0in' type=disc>
          <li class=MsoNormal style='mso-list:l1 level1 lfo3'><span lang=EN-GB
              style='mso-bidi-font-size:11.0pt'>SFDA Call center : 19999</span><span
              lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:
              Calibri'><o:p></o:p></span></li>
          <li class=MsoNormal style='mso-list:l1 level1 lfo3'><span lang=EN-GB
              style='mso-bidi-font-size:11.0pt'>E-mail: </span><span
              lang=EN-GB><a href="mailto:npc.drug@sfda.gov.sa"><span
              style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:Calibri;
              color:windowtext'>npc.drug@sfda.gov.sa</span></a></span><span
              lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:
              Calibri'><o:p></o:p></span></li>
          <li class=MsoNormal style='mso-list:l1 level1 lfo3'><span lang=EN-GB
              style='mso-bidi-font-size:11.0pt'>Website: </span><span
              lang=EN-GB><a href="https://ade.sfda.gov.sa/"><span
              style='mso-bidi-font-size:11.0pt'>https://ade.sfda.gov.sa/</span></a></span><span
              lang=EN-GB style='mso-bidi-font-size:11.0pt'> </span><span
              lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:
              Calibri'><o:p></o:p></span></li>
         </ul>
         <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
         </div>
         <![if !mso]></td>
        </tr>
       </table>
       <![endif]></v:textbox>
      <w:wrap type="square" anchorx="margin"/>
     </v:shape><![endif]--><img width="646" height="98" alt="Text Box: National Pharmacovigilance Centre ( NPC )
•	SFDA Call center : 19999
•	E-mail: npc.drug@sfda.gov.sa
•	Website: https://ade.sfda.gov.sa/ 

" src="file:///C:/Users/M564540/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" />Saudi Arabia</li></ul><p>&nbsp;</p><p><strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30 &deg;C. Store in the original package, in order to protect from moisture.</p><p><strong>&nbsp;</strong></p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a-What VIAGRA contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is sildenafil. Each orodispersible tablet contains 50&nbsp;mg of sildenafil (as the citrate salt).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>-&nbsp; microcrystalline cellulose, silica hydrophobic colloidal, croscarmellose sodium (see section 2 &ldquo;VIAGRA contains sodium&rdquo;), magnesium stearate, indigo carmine aluminium lake (E132), sucralose, mannitol, crospovidone, polyvinyl acetate, povidone,</p><p>-&nbsp; flavouring containing: maltodextrin and dextrin,</p><p>-&nbsp; natural flavouring containing: maltodextrin, glycerol (E422) and propylene glycol (E1520),</p><p>-&nbsp; lemon flavouring containing: maltodextrin and alpha‑tocopherol (E307)).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                VIAGRA orodispersible tablets are blue, diamond shape, marked “V50” on one side. The orodispersible tablets are provided in blister packs containing 2 tablets (one blister of 2 tablets)

 4 tablets (one blister of 4 tablets)

 8 tablets (two blisters each of 4 tablets)


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Upjohn EESV, Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, The Netherlands.</p><p><strong>Manufactured, Packed &amp; Released by:</strong></p><p>Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Poc&eacute;‑sur‑Cisse, France.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in August 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فياجرا على المادة الفعالة سيلدينافيل التي تنتمي لفئة من الأدوية تُدعى مثبطات إنزيم فسفوديستراز من النوع الخامس (PDE5). يعمل الدواء عن طريق المساعدة على ارتخاء الأوعية الدموية الموجودة في القضيب مما يسمح بتدفق الدم إلى القضيب عند التعرض للإثارة الجنسية. سيساعدك فياجرا على تحقيق الانتصاب فقط عند التعرض للإثارة الجنسية.</p><p dir="RTL">يستخدم فياجرا كعلاج للرجال البالغين الذي يعانون من خلل الانتصاب الذي يعرف أحيانًا بالضعف الجنسي. يُقصد بذلك عندما لا يستطيع الرجل تحقيق الانتصاب أو الحفاظ عليه بما يكفي للممارسات الجنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال فياجرا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه سيلدينافيل أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية تُدعى بمركبات النترات، حيث قد يؤدي الجمع بينهما إلى انخفاض خطير في ضغط الدم. أخبر طبيبك إذا كنت تتناول أيًا من هذه الأدوية التي تستخدم عادةً لعلاج الذبحة الصدرية (أو &quot;ألم الصدر&quot;). إذا كنت غير واثقٍ مما عليك فعله، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أي من الأدوية المعروفة بأنها مُصدرة لأكسيد النيتريك مثل نيتريت الأميل (&quot;<strong>حمضيات</strong>&quot;)، حيث قد يؤدي الجمع بينهما أيضًا إلى انخفاض خطير في ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول ريوسيجوات. يُستخدم هذا العقار لعلاج ارتفاع ضغط الدم الشرياني الرئوي (أي ارتفاع ضغط الدم في الرئتين) وارتفاع ضغط الدم الرئوي الناتج عن الانصمام الخثاري المزمن (أي ارتفاع ضغط الدم في الرئتين بسبب وجود تجلطات في الدم). ثبت أن مثبطات إنزيم فسفودايستراز من النوع الخامس (PDE5)، مثل فياجرا، تزيد من التأثيرات الخافضة لضغط الدم الخاصة بهذا الدواء. إذا كنت تتناول ريوسيجوات أو لم تكن واثقًا، فأخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات حادة في القلب أو الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت مؤخرًا بسكتةٍ دماغية أو بأزمةٍ قلبية، أو إّذا كنت تعاني من انخفاض ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرضٍ وراثي نادر بالعين (مثل التهاب الشبكية الصباغي ).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ما سبق أن أصبت بفقدان الرؤية الناتج عن اعتلال العصب البصري الأمامي الإقفاري غير المصحوب بالتهاب الشرايين (NAION).</p><p><strong>&nbsp;</strong></p><p><strong>الاحتياطات عند استعمال فياجرا</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل تناول فياجرا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بأنيميا الخلايا المنجلية (اعتلال يصيب خلايا الدم الحمراء) أو اللوكيميا (سرطان يصيب خلايا الدم) أو الورم النقوي المتعدد (سرطان يصيب نخاع العظم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تعاني من تشوهات في القضيب أو من داء بيروني.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات قلبية. ينبغي على طبيبك فحصك بعناية للتحقق مما إذا كان قلبك سيستطيع تحمل الإجهاد الزائد الناتج عن ممارسة الجماع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حاليًا من قرحة معدية أو مشكلات نزفية (مثل الهيموفيليا).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بضعف أو فقدان مفاجئ للرؤية، فأوقف تناول فياجرا واتصل بطبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم استخدام فياجرا مع أية علاجات أخرى لخلل الانتصاب، سواء فموية أو موضعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي ألا تستخدم فياجرا مع علاجات ارتفاع ضغط الدم الشرياني الرئوي (PAH) التي تحتوي على سيلدينافيل أو أي مثبطات PDE5 أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم تناول فياجرا إذا كنت لا تعاني من خلل الانتصاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي على السيدات عدم تناول فياجرا.</p><p dir="RTL">&nbsp;</p><p><em>اعتبارات خاصة للمرضى الذين يعانون من مشكلات بالكبد أو الكلى</em></p><p dir="RTL">عليك إبلاغ طبيبك إذا كنت تعاني من مشكلات بالكبد أو الكلى. فقد يقرر الطبيب إعطاءك جرعة أقل.</p><p dir="RTL">&nbsp;</p><p><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينبغي إعطاء فياجرا للأفراد الأقل من ١٨ عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية.</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتداخل فياجرا مع عمل بعض الأدوية الأخرى، خاصةً تلك المستخدمة لعلاج ألم الصدر. في حالات الطوارئ الطبية، عليك إخبار طبيبك أو الصيدلي أوالممرضة بأنك قد تناولت فياجرا وبتوقيت تناولك له. لا تتناول فياجرا مع أدوية أخرى ما لم يخبرك طبيبك بإمكانية فعل ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم تناول فياجرا إذا كنت تتناول أدوية تُدعى مركبات النترات، حيث قد يؤدي الجمع بين فياجرا وهذه الأدوية إلى انخفاض خطير في ضغط الدم. احرص دومًا على إخبار طبيبك أو الصيدلي أو الممرضة إذا كنت تتناول أي من هذه الأدوية التي تُستخدم عادةً لعلاج الذبحة الصدرية (أو &quot;ألم الصدر&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم تناول فياجرا إذا كنت تستخدم أي من الأدوية المعروفة بأنها مُصدرة لأكسيد النيتريك مثل نيتريت الأميل (&ldquo;حمضيات&rdquo;)، حيث قد يؤدي الجمع بينهما إلى انخفاض خطير في ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا ما كنت تتناول ريوسيجوات بالفعل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول أدوية تُعرف بمثبطات البروتياز، مثل تلك المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية (<strong>HIV</strong>)، فقد يبدأ طبيبك علاجك بأقل جرعة ممكنة (٢٥ ملجم من الأقراص المغلفة بطبقة رقيقة) من فياجرا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصاب بعض المرضى الذين يتلقون العلاج المحصر لمستقبلات ألفا لعلاج ارتفاع ضغط الدم أو تضخم البروستاتا، بالدوار أو الدوخة، ما قد يكون ناتجًا عن انخفاض ضغط الدم عند الجلوس أو القيام بسرعة. أصيب بعض المرضى بهذه الأعراض عند تناولهم فياجرا بالتزامن مع محصرات مستقبلات ألفا. تزداد احتمالات حدوث هذا خلال ٤ ساعات من تناول فياجرا. للحد من احتمالات حدوث هذه الأعراض، تنبغي عليك المداومة على جرعة يومية منتظمة من محصرات مستقبلات ألفا قبل بدء تناول فياجرا. قد يبدأ طبيبك علاجك بجرعة منخفضة (٢٥ ملجم من الأقراص المغلفة بطبقة رقيقة) من فياجرا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا ما كنت تتناول أدوية تحتوي علي ساكيوبتريل/ فالسارتان <strong>وهي </strong>تستخدم في علاج<strong>&nbsp; </strong>فشل القلب</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول فياجرا مع الطعام والشراب</strong></p><p dir="RTL"><strong>تناول فياجرا مع الكحوليات</strong></p><p dir="RTL">قد يسبب تناول الكحول خللًا مؤقتًا في قدرتك على تحقيق الانتصاب. لتحقيق أقصى منفعة من الدواء، يوصى بعدم الإفراط في تعاطي الكحوليات قبل تناول فياجرا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;فياجرا غير مُخصص للاستخدام من قبل السيدات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير فياجرا على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يسبب فياجرا الدوار وقد يؤثر على الرؤية. يجب أن تكون محيطًا بتأثير فياجرا عليك قبل الشروع في القيادة أو استخدام الماكينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات فياجرا</strong></p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>فياجرا</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ملي مول صوديوم (٢٣ ملجم) لكل قرص وهذا يعني أنه بشكل أساسي &quot;خال من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دومًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا مما عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة المبدئية الموصى بها هي ٥٠ ملجم.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong><em>ينبغي عدم تناول فياجرا أكثر من مرة واحدة يوميًا.</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول أقراص فياجرا سريعة الذوبان في الفم بالتزامن مع أقراص أخرى مغلفة بطبقة رقيقة تحتوي على سيلدينافيل، بما في ذلك أقراص فياجرا المغلفة بطبقة رقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عليك تناول فياجرا قبل حوالي ساعة واحدة من الشروع في ممارسة الجماع. تختلف المدة التي يستغرقها فياجرا ليبدء تأثيره في الظهور من شخص لآخر، ولكنها عادة تتراوح بين نصف ساعة إلى ساعة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ضع القرص سريع الذوبان في الفم على اللسان، وسوف يذوب خلال ثوان، ثم قم ببلعه مع اللعاب أو ببعض الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي تناول الأقراص سريعة الذوبان في الفم على معدة فارغة، حيث قد تستغرق وقتًا أطول قبل أن يظهر تأثيرها إذا ما تناولتها مع وجبة دسمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا احتجت إلى تناول قرص آخر ٥٠ ملجم سريع الذوبان لاستكمال جرعة تبلغ ١٠٠٠ ملجم، عليك الانتظار حتى يذوب القرص الأول تمامًا وتقوم بابتلاعه قبل أن تتناول القرص الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا شعرت أن تأثير فياجرا أقوى أو أضعف من اللازم، تحدث مع طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيساعدك فياجرا على تحقيق الانتصاب فقط عند التعرض للإثارة الجنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم يساعدك فياجرا على تحقيق الانتصاب، أو إذا لم يستمر الانتصاب لمدة كافية لإتمام ممارسة الجماع، فعليك إبلاغ طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p><strong>الجرعة الزائدة من فياجرا</strong></p><p dir="RTL">قد تتعرض لزيادة في عدد وشدة الآثار الجانبية. لا تزيد الجرعات الأعلى من ١٠٠٠ ملجم من فعالية الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<em>ينبغي عدم تناول عدد أقراص أكبر مما وصفه لك طبيبك. </em></p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك إذا تناولت عدد أقراص أكبر مما ينبغي.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك المزيد من الأسئلة حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع. وتكون الآثار الجانبية التي يتم الإبلاغ عنها بالتزامن مع استخدام فياجرا عادة خفيفة إلى متوسطة وتستمر لمدة قصيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أصبت بأي من الآثار الجانبية الخطيرة التالية، فأوقف تناول فياجرا والجأ للرعاية الطبية على الفور:</strong></p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">تفاعل حساسية (وهو <strong>غير شائع الحدوث، </strong>قد يصيب ما يصل إلى شخص واحد من كل ١٠٠٠٠ شخص)</li></ul><p dir="RTL">أعراض تتضمن حالات مفاجئة من أزيز الصدر وصعوبة التنفس أو الدوار وتورم الجفون أو الوجه أو الشفتين أو الحلق.</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">آلام الصدر، وهي <strong>غير شائعة</strong> الحدوث</li></ul><p dir="RTL">إذا ما حدث ذلك أثناء أو بعد الجماع:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - اجعل نفسك في وضع شبه جالس وحاول الاسترخاء.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - <strong>لا تستخدم مركبات النترات</strong> لعلاج آلام الصدر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;&nbsp; انتصاب مطول وأحيانًا مؤلم <strong>وهو نادر الحدوث </strong>(قد يصيب ما يصل إلى شخص واحد من كل ١٠٠٠٠٠٠ شخص)</p><p dir="RTL">&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ما تعرضت لانتصاب يستمر لأكثر من ٤ ساعات، فعليك الاتصال بطبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;&nbsp; ضعف أو فقدان مفاجئ للرؤية، وهذا <strong>نادر</strong> الحدوث</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong>&nbsp;&nbsp; تفاعلات جلدية خطيرة، وهذا <strong>نادر</strong> الحدوث</p><p dir="RTL">قد تتضمن الأعراض التقشر والتورم الحاد للبشرة وتقرح الفم والأعضاء التنسلية والمنطقة المحيطة بالعينين والحمى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong>&nbsp;&nbsp; النوبات، وهذا <strong>نادر</strong> الحدوث</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائع جدًا</strong> (قد تصيب أكثر من ١ من كل ١٠٠ أشخاص): الصداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائع</strong> (قد تصيب ما يصل إلى ١ من كل ١٠٠ أشخاص): الغثيان واحمرار الوجه والاحمرار المصحوب بسخونة (تتضمن الأعراض إحساسًا مفاجئًا بالسخونة في الجزء العلوي من جسمك) وعسر الهضم واصطباغ محيط الرؤية بلونٍ ما وتغيم الرؤية واضطراب الرؤية والزكام والدوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائع</strong> (قد تصيب ما يصل إلى ١ من كل ١٠٠٠٠ شخص): القيء والطفح الجلدي وتهيج العين واحمرار العين وألم العين رؤية ومضات من الضوء وسطوع الرؤية والحساسية تجاه الضوء وإدماع العين وقوة ضربات القلب وسرعة ضربات القلب وارتفاع ضغط الدم وانخفاض ضغط الدم وألم العضلات والشعور بالنعاس وانخفاض الإحساس باللمس والدوار وطنين الأذن وجفاف الفم وجيوب أنفية مسدودة أو مغلقة والتهاب بطانة الأنف (تتضمن الأعراض سيلان الأنف والعطس وانسداد الأنف) وألم في الجزء العلوي من البطن ومرض الارتجاع المعدي المريئي (تتضمن الأعراض حرقة في المعدة) ووجود دم في البول والشعور بألم في الذراعين أو الأرجل ونزيف في الأنف والشعور بالسخونة والشعور بالتعب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادر</strong> (قد تصيب ما يصل إلى ١ من كل ١٠٠٠٠٠ شخص): الإغماء والسكتة الدماغية والأزمة القلبية واضطراب نظم ضربات القلب وانخفاض مؤقت في تدفق الدم إلى بعض أجزاء الدماغ والشعور بتضيق الحلق وتخدر الفم ونزيف في الجزء الخلفي من العين ورؤية مزدوجة وانخفاض حدة الرؤية وإحساس غير طبيعي بالعين وتورم العين أو الجفن وظهور جزيئات أو نقاط صغيرة في مجال رؤيتك ورؤية هالات حول الأضواء وتوسع حدقة العين وتغير لون الجزء الأبيض من العين ونزيف من القضيب ووجود دم في المني وجفاف الأنف وتورم الجزء الداخلي من الأنف والشعور بتهيج وانخفاض مفاجئ للقدرة على السمع أو فقدانها بشكل مفاجئ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;تم الإبلاغ بشكل نادر عن حالات من الذبحة غير المستقرة (حالة قلبية) والموت المفاجئ في تجارب ما بعد مرحلة التسويق. والشيء المهم أن معظم، ولكن ليس كل، الرجال الذين تعرضوا لهذه الآثار الجانبية كانوا مصابين بالفعل بمشكلات قلبية قبل تناولهم لهذا الدواء. ليس من الممكن معرفة إذا ما كانت هذه الأحداث مرتبطة بشكل مباشر باستخدام فياجرا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، تحدث مع طبيبك أو الصيدلي. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">-&nbsp; المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>المملكة العربية السعودية:</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">- <em>الرجاء</em><em> </em><em>الاتصال</em><em> </em><em>بالمؤسسات</em><em> </em><em>والهيئات</em><em> </em><em>الوطنية</em><em> </em><em>في</em><em> </em><em>كل</em><em> </em><em>دولة</em><em>.</em></p></td></tr></tbody></table><p>دول الخليج الأخرى:</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد مرور تاريخ انتهاء الصلاحية المُدون على العبوة الكرتونية وشرائط البليستر بعد الرمز EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">يحفظ في درجة حرارة لا تزيد عن ٣٠ درجة مئوية. يُخزن في عبوته الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أية أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. تساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما هي محتويات فياجرا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي سيلدينافيل. يحتوي كل قرص سريع الذوبان في الفم على ٥٠٠ ملجم من سيلدينافيل (في صورة ملح السيترات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سليولوز بلوري مكروي، سيليكا غروانية لا تمتزج بالماء (طاردة للماء)، كروسكارميلوز الصوديوم (انظر القسم ٢ &quot;يحتوي فياجرا على الصوديوم&quot;)، ستيارات المغنيسيوم، صبغة ليك ألومنيوم قرمزية نيلية، (E132)، سكرالوز، مانيتول، كروسبوفيدون، أسيتات بولي فينيل، بوفيدون،</p><p dir="RTL">-&nbsp; مُكسبات طعم تحتوي على: مالتودكسترين ودكسترين،</p><p dir="RTL">-&nbsp; مكسبات طعم طبيعية تحتوي على: مالتودكسترين وجليسرول (E422) وجليكول البروبيلين (E1520)،</p><p dir="RTL">-&nbsp; مكسبات طعم الليمون تحتوي على: مالتودكسترين وألفاتوكوفيرول (E307)).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما هو الشكل الصيدلاني لفياجرا ووصفه وحجم عبوته</strong></p><p dir="RTL">أقراص فياجرا سريعة الذوبان في الفم زرقاء اللون مُعيَّنة الشكل وتحمل الرمز &quot;V50&quot; على أحد جانبيها. تتوفر الأقراص سريعة الذوبان في الفم في عبوات من شرائط بليستر تحتوي على</p><p dir="RTL">&nbsp;قرصين (شريط بليستر واحد يحتوي علي قرصين)</p><p dir="RTL">&nbsp;أربعة أقراص (شريط بليستر واحد يحتوي علي أربعة أقراص)</p><p dir="RTL">&nbsp;ثمانية أقراص (شريطين بليستر يحتوي كل منهما علي أربعة أقراص)</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p dir="RTL">آبجون اي اي اس في، هولندا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تصنيع وتعبئة وتوزيع:</strong></p><p dir="RTL">فاريفا امبويس ، فرنسا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌د-	تمت مراجعة هذه النشرة بتاريخ أغسطس 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VIAGRA 50 mg orodispersible tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains sildenafil citrate equivalent to 50 mg of sildenafil.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Orodispersible tablet.

Blue, rounded, diamond shaped tablets, marked “V50” on one side and plain on the other.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VIAGRA is indicated in adult men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.</p><p>&nbsp;</p><p>In order for VIAGRA to be effective, sexual stimulation is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em>Use in adults</em></p><p>Viagra should be taken as needed approximately one hour before sexual activity. The recommended dose is 50&nbsp;mg taken on an empty stomach as concomitant intake with food delays absorption and delays the effect of the orodispersible tablet (see section 5.2).</p><p>&nbsp;</p><p>Based on efficacy and tolerability, the dose may be increased to 100&nbsp;mg. The maximum recommended dose is 100&nbsp;mg. For patients requiring a dose increase to 100&nbsp;mg, two 50&nbsp;mg orodispersible tablets should be administered sequentially. The maximum recommended dosing frequency is once per day. If a dose of 25<strong>&nbsp;</strong>mg is required, the use of the 25&nbsp;mg film‑coated tablets should be recommended.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em><u>Elderly</u></em></p><p>Dosage adjustments are not required in elderly patients (&ge; 65 years old).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>The dosing recommendations described in &lsquo;Use in adults&rsquo; apply to patients with mild to moderate renal impairment (creatinine clearance = 30‑80&nbsp;mL/min).</p><p>&nbsp;</p><p>Since sildenafil clearance is reduced in patients with severe renal impairment (creatinine clearance</p><p>&lt;30&nbsp;mL/min) a 25&nbsp;mg dose should be considered. Based on efficacy and tolerability the dose may be increased step‑wise to 50&nbsp;mg up to 100&nbsp;mg as necessary.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Since sildenafil clearance is reduced in patients with hepatic impairment (e.g. cirrhosis) a 25&nbsp;mg dose should be considered. Based on efficacy and tolerability, the dose may be increased step‑wise to 50&nbsp;mg up to 100&nbsp;mg as necessary.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>VIAGRA is not indicated for individuals below 18 years of age.</p><p>&nbsp;</p><p><em><u>Use in patients taking other medicinal products</u></em></p><p>With the exception of ritonavir for which co‑administration with sildenafil is not advised (see section 4.4), a starting dose of 25&nbsp;mg should be considered in patients receiving concomitant treatment with CYP3A4 inhibitors (see section 4.5).</p><p>&nbsp;</p><p>In order to minimise the potential of developing postural hypotension in patients receiving alpha‑blocker treatment, patients should be stabilised on alpha‑blocker therapy prior to initiating sildenafil treatment. In addition, initiation of sildenafil at a dose of 25&nbsp;mg should be considered (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For oral use.</p><p>&nbsp;</p><p>The orodispersible tablet should be placed in the mouth, on the tongue, and allowed to disintegrate before swallowing with or without water. It should be taken immediately upon removal from the blister. For patients requiring a second 50&nbsp;mg orodispersible tablet to make a 100&nbsp;mg dose, the second tablet should be taken upon full disintegration of the first tablet.</p><p>&nbsp;</p><p>There is a significant delay in absorption when orodispersible tablets are taken with a high fat meal compared to the fasted state (see section 5.2). It is recommended that orodispersible tablets be taken on an empty stomach. Orodispersible tablets can be taken with or without water.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Consistent with its known effects on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form is therefore contraindicated. 

The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).

Agents for the treatment of erectile dysfunction, including sildenafil, should not be used in men for whom sexual activity is inadvisable (e.g. patients with severe cardiovascular disorders such as unstable angina or severe cardiac failure).

VIAGRA is contraindicated in patients who have loss of vision in one eye because of non arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).

The safety of sildenafil has not been studied in the following sub groups of patients and its use is therefore contraindicated: severe hepatic impairment, hypotension (blood pressure <90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes, before pharmacological treatment is considered.</p><p>&nbsp;</p><p><u>Cardiovascular risk factors</u></p><p>&nbsp;</p><p>Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Sildenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1). Prior to prescribing sildenafil, physicians should carefully consider whether their patients with certain underlying conditions could be adversely affected by such vasodilatory effects, especially in combination with sexual activity. Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (e.g., aortic stenosis, hypertrophic obstructive cardiomyopathy), or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure.</p><p>&nbsp;</p><p>VIAGRA potentiates the hypotensive effect of nitrates (see section 4.3).</p><p>&nbsp;</p><p>Serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported post‑marketing in temporal association with the use of VIAGRA. Most, but not all, of these patients had pre‑existing cardiovascular risk factors. Many events were reported to occur during or shortly after sexual intercourse and a few were reported to occur shortly after the use of VIAGRA without sexual activity. It is not possible to determine whether these events are related directly to these factors or to other factors.</p><p>&nbsp;</p><p><u>Priapism</u></p><p>&nbsp;</p><p>Agents for the treatment of erectile dysfunction, including sildenafil, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie&rsquo;s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).</p><p>&nbsp;</p><p>Prolonged erections and priapism have been reported with sildenafil in post-marketing experience. In the event of an erection that persists longer than 4&nbsp;hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result.</p><p>&nbsp;</p><p><u>Concomitant use with other PDE5 inhibitors or other treatments for erectile dysfunction</u></p><p>&nbsp;</p><p>The safety and efficacy of combinations of sildenafil with other PDE5 Inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil (REVATIO), or other treatments for erectile dysfunction have not been studied. Therefore the use of such combinations is not recommended.</p><p>&nbsp;</p><p><u>Effects on vision</u></p><p><em>&nbsp;</em></p><p><em>Cases of v</em><em>isual defects have been reported spontaneously in connection with the intake of&nbsp;sildenafil and other PDE5 inhibitors </em><em>(see section 4.8). Cases of non‑arteritic </em>anterior <em>ischaemic optic neuropathy, a rare condition, have been reported </em>spontaneously and in an observational study <em>in connection with the intake of&nbsp;sildenafil and other PDE5 inhibitors (see section 4.8)</em><em>. Patients should be advised that in the event of any sudden visual defect, they should stop taking VIAGRA and consult a physician immediately (see section 4.3).</em></p><p>&nbsp;</p><p><em><u>Concomitant use with ritonavir</u></em></p><p>&nbsp;</p><p>Co‑administration of sildenafil with ritonavir is not advised (see section 4.5).</p><p>&nbsp;</p><p><u>Concomitant use with alpha‑blockers</u></p><p>&nbsp;</p><p>Caution is advised when sildenafil is administered to patients taking an alpha‑blocker, as the co‑administration may lead to symptomatic hypotension in a few susceptible individuals (see section 4.5). This is most likely to occur within 4 hours post sildenafil dosing. In order to minimise the potential for developing postural hypotension, patients should be hemodynamically stable on alpha‑blocker therapy prior to initiating sildenafil treatment. Initiation of sildenafil at a dose of 25&nbsp;mg should be considered (see section 4.2). In addition, physicians should advise patients what to do in the event of postural hypotensive symptoms.</p><p>&nbsp;</p><p><u>Effect on bleeding</u></p><p>&nbsp;</p><p>Studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside <em>in vitro</em>. There is no safety information on the administration of sildenafil to patients with bleeding disorders or active peptic ulceration. Therefore sildenafil should be administered to these patients only after careful benefit‑risk assessment.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet. Patients on low sodium diets can be informed that this medicinal product is essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p><p><u>Women</u></p><p>&nbsp;</p><p>VIAGRA is not indicated for use by women.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Effects of other medicinal products on sildenafil</u></p><p>&nbsp;</p><p><em>In vitro</em> <em>studies</em></p><p>Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance.</p><p>&nbsp;</p><p><em>In vivo studies</em></p><p>Population pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co‑administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, cimetidine). Although no increased incidence of adverse events was observed in these patients, when sildenafil is administered concomitantly with CYP3A4 inhibitors, a starting dose of 25&nbsp;mg should be considered.</p><p>&nbsp;</p><p>Co‑administration of the HIV protease inhibitor ritonavir, which is a<em> </em>highly potent P450 inhibitor, at steady state (500&nbsp;mg twice daily) with sildenafil (100&nbsp;mg single dose) resulted in a 300% (4‑fold) increase in sildenafil C<sub>max</sub> and a 1,000% (11‑fold) increase in sildenafil plasma AUC. At 24 hours, the plasma levels of sildenafil were still approximately 200&nbsp;ng/mL, compared to approximately 5&nbsp;ng/mL when sildenafil was administered alone. This is consistent with ritonavir&rsquo;s marked effects on a broad range of P450 substrates. Sildenafil had no effect on ritonavir pharmacokinetics. Based on these pharmacokinetic results co‑administration of sildenafil with ritonavir is not advised (see section 4.4) and in any event the maximum dose of sildenafil should under no circumstances exceed 25&nbsp;mg within 48 hours.</p><p>&nbsp;</p><p>Co‑administration of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state (1200&nbsp;mg three times a day) with sildenafil (100&nbsp;mg single dose) resulted in a 140% increase in sildenafil C<sub>max</sub> and a 210% increase in sildenafil AUC. Sildenafil had no effect on saquinavir pharmacokinetics (see section 4.2). Stronger CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected to have greater effects.</p><p>&nbsp;</p><p>When a single 100&nbsp;mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500&nbsp;mg twice daily for 5&nbsp;days), there was a 182% increase in sildenafil systemic exposure (AUC). In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500&nbsp;mg daily for 3 days) on the AUC, C<sub>max</sub>, t<sub>max</sub>, elimination rate constant, or subsequent half‑life of sildenafil or its principal circulating metabolite. Cimetidine (800 mg), a cytochrome P450 inhibitor and non‑specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co‑administered with sildenafil (50&nbsp;mg) to healthy volunteers.</p><p>&nbsp;</p><p>Grapefruit juice is a weak inhibitor of CYP3A4 gut wall metabolism and may give rise to modest increases in plasma levels of sildenafil.</p><p>&nbsp;</p><p>Single doses of antacid (magnesium hydroxide/aluminium hydroxide) did not affect the bioavailability of sildenafil.</p><p>&nbsp;</p><p>Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta‑adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates). In a study of healthy male volunteers, co-administration of the endothelin antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in 62.6% and 55.4% decrease in sildenafil AUC and C<sub>max</sub>, respectively. Therefore, concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma concentrations of sildenafil.</p><p>&nbsp;</p><p>Nicorandil is a hybrid of potassium channel activator and nitrate. Due to the nitrate component it has the potential to result in a serious interaction with sildenafil.</p><p>&nbsp;</p><p><u>Effects of sildenafil on other medicinal products</u></p><p>&nbsp;</p><p><em>In vitro studies</em></p><p>Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC<sub>50 </sub>&gt;150 &mu;M). Given sildenafil peak plasma concentrations of approximately 1&nbsp;&mu;M after recommended doses, it is unlikely that VIAGRA will alter the clearance of substrates of these isoenzymes.</p><p>&nbsp;</p><p>There are no data on the interaction of sildenafil and non‑specific phosphodiesterase inhibitors such as theophylline or dipyridamole.</p><p>&nbsp;</p><p><em>In vivo studies</em></p><p>Consistent with its known effects on the nitric oxide/cGMP pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co‑administration with nitric oxide donors or nitrates in any form is therefore contraindicated (see section 4.3).</p><p>&nbsp;</p><p>Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including sildenafil, is contraindicated (see section 4.3).</p><p>&nbsp;</p><p>Concomitant administration of sildenafil to patients taking alpha‑blocker therapy may lead to symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug‑drug interaction studies, the alpha‑blocker doxazosin (4&nbsp;mg and 8&nbsp;mg) and sildenafil (25&nbsp;mg, 50&nbsp;mg, or 100&nbsp;mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg, 9/5&nbsp;mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports of patients who experienced symptomatic postural hypotension. These reports included dizziness and light‑headedness, but not syncope.</p><p>&nbsp;</p><p>No significant interactions were shown when sildenafil (50&nbsp;mg) was co‑administered with tolbutamide (250&nbsp;mg) or warfarin (40&nbsp;mg), both of which are metabolised by CYP2C9.</p><p>&nbsp;</p><p>Sildenafil (50&nbsp;mg) did not potentiate the increase in bleeding time caused by acetyl salicylic acid (150&nbsp;mg).</p><p>&nbsp;</p><p>Sildenafil (50&nbsp;mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 80&nbsp;mg/dl.</p><p>&nbsp;</p><p>Pooling of the following classes of antihypertensive medication: diuretics, beta‑blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive medicinal products (vasodilator and centrally‑acting), adrenergic neurone blockers, calcium channel blockers and alpha‑adrenoceptor blockers, showed no difference in the side effect profile in patients taking sildenafil compared to placebo treatment. In a specific interaction study, where sildenafil (100&nbsp;mg) was co‑administered with amlodipine in hypertensive patients, there was an additional reduction on supine systolic blood pressure of 8&nbsp;mmHg. The corresponding additional reduction in supine diastolic blood pressure was 7&nbsp;mmHg. These additional blood pressure reductions were of a similar magnitude to those seen when sildenafil was administered alone to healthy volunteers (see section 5.1).</p><p>&nbsp;</p><p>Sildenafil (100&nbsp;mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates.</p><p>&nbsp;</p><p>In healthy male volunteers, sildenafil at steady state (80 mg t.i.d.) resulted in a 49.8% increase in bosentan AUC and a 42% increase in bosentan C<sub>max</sub> (125 mg b.i.d.).</p><p>&nbsp;</p><p>Addition of a single dose of sildenafil to sacubitril/valsartan at steady state in patients with hypertension was associated with a significantly greater blood pressure reduction compared to administration of sacubitril/valsartan alone. Therefore, caution should be exercised when sildenafil is initiated in patients treated with sacubitril/valsartan.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VIAGRA is not indicated for use by women.</p><p>&nbsp;</p><p>There are no adequate and well‑controlled studies in pregnant or breast-feeding women.</p><p>No relevant adverse effects were found in reproduction studies in rats and rabbits following oral administration of sildenafil.</p><p>&nbsp;</p><p>There was no effect on sperm motility or morphology after single 100&nbsp;mg oral doses of sildenafil in healthy volunteers (see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VIAGRA may have a minor influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>As dizziness and altered vision were reported in clinical trials with sildenafil, patients should be aware of how they react to VIAGRA, before driving or operating machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>The safety profile of VIAGRA is based on 9,570 patients in 74 double-blind placebo‑controlled clinical studies. The most commonly reported adverse reactions in clinical studies among sildenafil treated patients were headache, flushing, dyspepsia, nasal congestion, dizziness, nausea, hot flush, visual disturbance, cyanopsia and vision blurred.</p><p>&nbsp;</p><p>Adverse reactions from post‑marketing surveillance has been gathered covering an estimated period &gt;10 years. Because not all adverse reactions are reported to the Marketing Authorisation Holder and included in the safety database, the frequencies of these reactions cannot be reliably determined.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000).. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1: Medically important adverse reactions reported at an incidence greater than placebo in controlled clinical studies and medically important adverse reactions reported through post‑marketing surveillance</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong><em>(</em></strong><strong><em>&sup3;</em></strong><strong><em> 1/10)</em></strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong><em>(</em></strong><strong><em>&sup3;</em></strong><strong><em> 1/100 and &lt;1/10)</em></strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong><em>(</em></strong><strong><em>&sup3;</em></strong><strong><em> 1/1,000 and &lt;1/100)</em></strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong><em>(</em></strong><strong><em>&sup3;</em></strong><strong><em> 1/10,000 and &lt;1/1,000)</em></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Somnolence, Hypoaesthesia</p></td><td style="vertical-align:top"><p>Cerebrovascular accident,</p><p>Transient ischaemic attack, Seizure<sup>*</sup>, Seizure recurrence,<sup>*</sup> Syncope</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual colour distortions**, Visual disturbance, Vision blurred</p></td><td style="vertical-align:top"><p>Lacrimation disorders***, Eye pain, Photophobia, Photopsia, Ocular hyperaemia, Visual brightness, Conjunctivitis</p></td><td style="vertical-align:top"><p>Non‑arteritic anterior ischaemic optic neuropathy (NAION)<sup>*</sup>, Retinal vascular occlusion<sup>*</sup>, Retinal haemorrhage, Arteriosclerotic retinopathy, Retinal disorder, Glaucoma, Visual field defect, Diplopia, Visual acuity reduced, Myopia, Asthenopia, Vitreous floaters, Iris disorder, Mydriasis, Halo vision, Eye oedema, Eye swelling, Eye disorder, Conjunctival hyperaemia, Eye irritation, Abnormal sensation in eye, Eyelid oedema, Scleral discoloration</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo, Tinnitus</p></td><td style="vertical-align:top"><p>Deafness</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia, Palpitations</p></td><td style="vertical-align:top"><p>Sudden cardiac death<sup>*</sup>, Myocardial infarction, Ventricular arrhythmia<sup>*</sup>, Atrial fibrillation, Unstable angina</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Flushing, Hot flush</p></td><td style="vertical-align:top"><p>Hypertension, Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nasal congestion</p></td><td style="vertical-align:top"><p>Epistaxis, Sinus congestion</p></td><td style="vertical-align:top"><p>Throat tightness, Nasal oedema, Nasal dryness</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea, Dyspepsia</p></td><td style="vertical-align:top"><p>Gastro oesophagael reflux disease, Vomiting, Abdominal pain upper, Dry mouth</p></td><td style="vertical-align:top"><p>Hypoaesthesia oral</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Stevens‑Johnson Syndrome (SJS)<sup>*</sup>, Toxic Epidermal Necrolysis (TEN)<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia, Pain in extremity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Penile haemorrhage, Priapism<sup>*</sup>, Haematospermia, Erection increased</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chest pain, Fatigue, Feeling hot</p></td><td style="vertical-align:top"><p>Irritability</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Heart rate increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>*</strong>Reported during post-marketing surveillance only</p><p>**Visual colour distortions: Chloropsia, Chromatopsia, Cyanopsia, Erythropsia and Xanthopsia</p><p>***Lacrimation disorders: Dry eye, Lacrimal disorder and Lacrimation increased</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after market authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions&nbsp; according to their local country requirements.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:615px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre ( NPC )</strong></p><p>&middot;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website :https://ade.sfda.gov.sa/&nbsp;&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In single dose volunteer studies of doses up to 800&nbsp;mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased. Doses of 200&nbsp;mg did not result in increased efficacy but the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, altered vision) was increased.</p><p>&nbsp;</p><p>In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and not eliminated in the urine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</p><p>&nbsp;</p><p>Pharmacotherapeutic group: Urologicals; Drugs used in erectile dysfunction, ATC Code: G04B E03.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Sildenafil is an oral therapy for erectile dysfunction. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis.</p><p>&nbsp;</p><p>The physiological mechanism responsible for erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood.</p><p>&nbsp;</p><p>Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP. Sildenafil has a peripheral site of action on erections. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>Studies <em>in vitro</em> have shown that sildenafil is selective for PDE5, which is involved in the erection process. Its effect is more potent on PDE5 than on other known phosphodiesterases. There is a 10‑fold selectivity over PDE6 which is involved in the phototransduction pathway in the retina. At maximum recommended doses, there is an 80‑fold selectivity over PDE1, and over 700‑fold over PDE2, 3, 4, 7, 8, 9, 10 and 11. In particular, sildenafil has greater than 4,000‑fold selectivity for PDE5 over PDE3, the cAMP‑specific phosphodiesterase isoform involved in the control of cardiac contractility.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p>Two clinical studies were specifically designed to assess the time window after dosing during which sildenafil could produce an erection in response to sexual stimulation. In a penile plethysmography (RigiScan) study of fasted patients, the median time to onset for those who obtained erections of 60% rigidity (sufficient for sexual intercourse) was 25 minutes (range 12‑37 minutes) on sildenafil. In a separate RigiScan study, sildenafil was still able to produce an erection in response to sexual stimulation 4‑5 hours post‑dose.</p><p>&nbsp;</p><p>Sildenafil causes mild and transient decreases in blood pressure which, in the majority of cases, do not translate into clinical effects. The mean maximum decreases in supine systolic blood pressure following 100&nbsp;mg oral dosing of sildenafil was 8.4&nbsp;mmHg. The corresponding change in supine diastolic blood pressure was 5.5&nbsp;mmHg. These decreases in blood pressure are consistent with the vasodilatory effects of sildenafil, probably due to increased cGMP levels in vascular smooth muscle. Single oral doses of sildenafil up to 100&nbsp;mg in healthy volunteers produced no clinically relevant effects on ECG.</p><p>&nbsp;</p><p>In a study of the hemodynamic effects of a single oral 100&nbsp;mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (&gt;70% stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7% and 6% respectively compared to baseline. Mean pulmonary systolic blood pressure decreased by 9%. Sildenafil showed no effect on cardiac output, and did not impair blood flow through the stenosed coronary arteries.</p><p>&nbsp;</p><p>A double‑blind, placebo‑controlled exercise stress trial evaluated 144 patients with erectile dysfunction and chronic stable angina who regularly received anti‑anginal medicinal products (except nitrates). The results demonstrated no clinically relevant differences between sildenafil and placebo in time to limiting angina.</p><p>&nbsp;</p><p>Mild and transient differences in colour discrimination (blue/green) were detected in some subjects using the Farnsworth‑Munsell 100 hue test at 1 hour following a 100&nbsp;mg dose, with no effects evident after 2 hours post‑dose. The postulated mechanism for this change in colour discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo‑controlled study of patients with documented early age‑related macular degeneration (n=9), sildenafil (single dose, 100&nbsp;mg) demonstrated no significant changes in the visual tests conducted (visual acuity, Amsler grid, colour discrimination simulated traffic light, Humphrey perimeter and photostress).</p><p>&nbsp;</p><p>There was no effect on sperm motility or morphology after single 100&nbsp;mg oral doses of sildenafil in healthy volunteers (see section 4.6).</p><p>&nbsp;</p><p><em>Further information on clinical trials</em></p><p>In clinical trials sildenafil was administered to more than 8000 patients aged 19‑87. The following patient groups were represented: elderly (19.9%), patients with hypertension (30.9%), diabetes mellitus (20.3%), ischaemic heart disease (5.8%), hyperlipidaemia (19.8%), spinal cord injury (0.6%), depression (5.2%), transurethral resection of the prostate (3.7%), radical prostatectomy (3.3%). The following groups were not well represented or excluded from clinical trials: patients with pelvic surgery, patients post‑radiotherapy, patients with severe renal or hepatic impairment and patients with certain cardiovascular conditions (see section 4.3).</p><p>&nbsp;</p><p>In fixed dose studies, the proportions of patients reporting that treatment improved their erections were 62% (25&nbsp;mg), 74% (50&nbsp;mg) and 82% (100&nbsp;mg) compared to 25% on placebo. In controlled clinical trials, the discontinuation rate due to sildenafil was low and similar to placebo.</p><p>Across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84%), mixed erectile dysfunction (77%), organic erectile dysfunction (68%), elderly (67%), diabetes mellitus (59%), ischaemic heart disease (69%), hypertension (68%), TURP (61%), radical prostatectomy (43%), spinal cord injury (83%), depression (75%). The safety and efficacy of sildenafil was maintained in long‑term studies.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with VIAGRA in all subsets of the paediatric population for the treatment of erectile dysfunction. See 4.2 for information on paediatric use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><em>&nbsp;</em></p><p>Sildenafil is rapidly absorbed. Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. The mean absolute oral bioavailability is 41% (range 25‑63%). After oral dosing of sildenafil AUC and C<sub>max</sub> increase in proportion with dose over the recommended dose range (25‑100&nbsp;mg).</p><p>&nbsp;</p><p>When film‑coated tablets are taken with food, the rate of absorption of sildenafil is reduced with a mean delay in t<sub>max</sub> of 60 minutes and a mean reduction in C<sub>max </sub>of 29%.</p><p>&nbsp;</p><p>In a clinical study in 36 healthy males 45 years or older, 50&nbsp;mg orodispersible tablets administered without water were observed to be bioequivalent to the 50&nbsp;mg film‑coated tablets. In the same study, the AUC was unchanged but the mean C<sub>max</sub> was 14% lower when 50&nbsp;mg orodispersible tablets were administered with water compared to 50&nbsp;mg film‑coated tablet.</p><p>&nbsp;</p><p>When orodispersible tablets is taken with a high fat meal, the rate of absorption of sildenafil is reduced, median T<sub>max</sub> is delayed by about 3.4 hours and mean C<sub>max</sub> and AUC are reduced respectively by about 59% and 12%, compared to administration of orodispersible tablets under fasting conditions (See Section 4.2).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The mean steady state volume of distribution (V<sub>d</sub>) for sildenafil is 105&nbsp;l, indicating distribution into the tissues. After a single oral dose of 100&nbsp;mg, the mean maximum total plasma concentration of sildenafil is approximately 440&nbsp;ng/mL (CV 40%). Since sildenafil (and its major circulating N‑desmethyl metabolite) is 96% bound to plasma proteins, this results in the mean maximum free plasma concentration for sildenafil of 18&nbsp;ng/mL (38&nbsp;nM). Protein binding is independent of total drug concentrations.</p><p>&nbsp;</p><p>In healthy volunteers receiving sildenafil (100&nbsp;mg single dose), less than 0.0002% (average 188&nbsp;ng) of the administered dose was present in ejaculate 90 minutes after dosing.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N‑demethylation of sildenafil. This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an <em>in vitro</em> potency for PDE5 approximately 50% that of the parent drug. Plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil. The N‑desmethyl metabolite is further metabolised, with a terminal half‑life of approximately 4&nbsp;h.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>The total body clearance of sildenafil is 41&nbsp;L/h with a resultant terminal phase half‑life of 3‑5&nbsp;h. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of administered oral dose).</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>Healthy, elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 90% higher plasma concentrations of sildenafil and the active N‑desmethyl metabolite compared to those seen in healthy younger volunteers (18‑45 years). Due to age‑differences in plasma protein binding, the corresponding increase in free sildenafil plasma concentration was approximately 40%.</p><p>&nbsp;</p><p><em>Renal insufficiency</em></p><p>In volunteers with mild to moderate renal impairment (creatinine clearance = 30‑80 mL/min), the pharmacokinetics of sildenafil were not altered after receiving a 50&nbsp;mg single oral dose. The mean AUC and C<sub>max</sub> of the N‑desmethyl metabolite increased up to 126% and up to 73% respectively, compared to age‑matched volunteers with no renal impairment. However, due to high inter‑subject variability, these differences were not statistically significant. In volunteers with severe renal impairment (creatinine clearance &lt;30&nbsp;mL/min), sildenafil clearance was reduced, resulting in mean increases in AUC and C<sub>max</sub> of 100% and 88% respectively compared to age‑matched volunteers with no renal impairment. In addition, N‑desmethyl metabolite AUC and C<sub>max</sub> values were significantly increased by 200% and 79% respectively.</p><p>&nbsp;</p><p><em>Hepatic insufficiency</em></p><p>In volunteers with mild to moderate hepatic cirrhosis (Child‑Pugh A and B) sildenafil clearance was reduced, resulting in increases in AUC (84%) and C<sub>max</sub> (47%) compared to age‑matched volunteers with no hepatic impairment. The pharmacokinetics of sildenafil in patients with severely impaired hepatic function have not been studied.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction and development.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</p><p>&nbsp;</p><p>Microcrystalline cellulose</p><p>Silica, hydrophobic colloidal</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p><p>Indigo carmine aluminium lake (E132)</p><p>Sucralose</p><p>Mannitol</p><p>Crospovidone</p><p>Polyvinyl acetate</p><p>Povidone</p><p>&nbsp;</p><p>Flavouring contains:</p><p>Maltodextrin</p><p>Dextrin</p><p>&nbsp;</p><p>Natural flavouring contains:</p><p>Maltodextrin</p><p>Glycerol (E422)</p><p>Propylene glycol (E1520)</p><p>&nbsp;</p><p>Lemon flavouring contains:</p><p>Maltodextrin</p><p>Alpha‑tocopherol (E307)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use VIAGRA orodispersible tablets after the expiry date which is stated on the carton / Blister label after EXP:. The expiry date refers to the last day of that month.

Shelf life: 36 months.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>Do not store above 30&deg;C</p><p>Store in the original package in order to protect from moisture.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium blisters in cartons of 2, 4, or 8 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Upjohn EESV, Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, The Netherlands.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>